Form 4: Gilead CFO Andrew Dickinson Executes Stock Transaction

Gilead Sciences CFO Andrew D. Dickinson acquired 2,796 shares via restricted stock unit vesting and disposed of 1,341 shares to cover tax obligations.

Summary

• CFO Andrew D. Dickinson acquired 2,796 shares of Gilead Sciences common stock on June 10, 2026, through the vesting of restricted stock units (RSUs).
• A total of 1,341 shares were withheld by the company at a price of $121.48 per share to satisfy tax withholding requirements related to the vesting event.
• Following these transactions, the CFO maintains a direct beneficial ownership of 174,646 shares of Gilead Sciences common stock.
• The underlying RSUs follow a 4-year vesting schedule with 25% vesting on the first anniversary and 6.25% vesting quarterly thereafter.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event, as it represents standard executive compensation activity rather than a discretionary trade.

Positives

• The transaction reflects the standard equity compensation vesting process for executive leadership.
• The CFO retains a significant equity stake of 174,646 shares, aligning interests with shareholders.

Negatives

• The transaction involved a net reduction in total shares held by the executive due to tax withholding requirements.

Risks

• None identified; this is a routine administrative filing regarding executive compensation.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a routine disclosure of executive equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting and tax-related sales by C-suite executives are standard corporate governance practices and generally do not signal changes in management sentiment regarding company performance.

Comparison to Industry Standards

• The equity compensation structure is consistent with standard practices for large-cap biopharmaceutical companies.
• The use of net-settlement for tax obligations is a common industry practice to manage executive tax liabilities.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine part of executive compensation packages.

Next Steps

• Continued vesting of remaining 27,851 restricted stock units according to the established 4-year schedule.

Key Dates

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, Executive Compensation, CFO